Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity
Securities
Market Information
Our publicly traded Common Stock and warrants
are currently listed on the Nasdaq Capital Market under the symbols “CDIO” and “CDIOW,” respectively. Prior to
the consummation of the Business Combination on October 25, 2022, Mana’s units, Common Stock, public warrants and rights were listed
on the Nasdaq Global Select Market under the symbols “MAAQU,” “MAAQ,” “MAAQW” and “MAAQR,”
respectively. There was no public trading market for Legacy Cardio’s equity.
Holders
As of March 27, 2023, there were 91 holders
of record of our common stock and ten holders of record of our Public Warrants and Sponsor Warrants. In addition, we have approximately
73 holders of private placement warrants, the majority of which have been registered for resale on a registration statement on Form S-1
that the SEC declared effective on January 24, 2023.
The number of record holders of our Common Stock
and Public Warrants was determined from the records of our transfer agent and does not include beneficial owners of any of our securities
whose securities are held in the names of various security brokers, dealers, and registered clearing agencies.
The transfer agent for our common stock and
warrant agent for our warrants is Continental Stock Transfer & Trust Company.
Dividends
We have not declared or paid any cash dividends
on our common stock. To date we have utilized all available cash to finance our operations. Payment of cash dividends in the future will
be at the discretion of our Board of Directors and will depend upon our earnings levels, capital requirements, any restrictive loan covenants
and other factors the Board considers relevant.
70
Warrants
At March 27, 2022, there were 7,854,620 warrants
outstanding for the purchase of Company Common Stock. Refer to Note7 to the consolidated financial statements included in this Annual
Report on Form 10-K for additional information relating to outstanding warrants.
Securities Authorized for Issuance Under
Equity Compensation Plans
See Part
III, Item 11, “Executive Compensation,” for information about securities authorized for
issuance under the Company’s equity compensation plan.
Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
None.
Item 6. [Reserved]
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.